Subscribe To

Price Alert Latest News Economic Calendar News

TRVI / Trevi Therapeutics (TRVI) Spikes 20% on Positive Clinical Data

Trevi Therapeutics (TRVI) stock is flying higher Wednesday following the release of positive trial data for its skin disease treatment! The post Trevi Therapeutics (TRVI) Spikes 20% on Positive Clinical Data appeared first on InvestorPlace. Read More

Demo Live Account See Partner Details

Content Topics

Trevi

Therapeutics

TRVI

Spikes

Positive

Clinical

Data

trvi

Stock

Posted: Jun 29 2022, 10:51

Author Name: InvestorPlace

TRVI News

By Zacks Investment Research
October 11, 2023

Trevi Therapeutics, Inc. (TRVI) Upgraded to Buy: Here's What You Should Know

Trevi Therapeutics, Inc. (TRVI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This m

By Seeking Alpha
August 10, 2023

Trevi Therapeutics, Inc. (TRVI) Q2 2023 Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jennifer Good - President and

By Seeking Alpha
March 16, 2023

Trevi Therapeutics, Inc. (TRVI) Q4 2022 Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Jennifer Good - President & Ch

By Seeking Alpha
November 13, 2022

Trevi Therapeutics, Inc. (TRVI) Q3 2022 Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Jennifer Good - President a

By PennyStocks
July 4, 2022

How to Find Trending Penny Stocks in 2022

Tips for making a list of trending penny stocks in 2022 The post How to Find Trending Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Pick

By InvestorPlace
June 29, 2022

Trevi Therapeutics (TRVI) Spikes 20% on Positive Clinical Data

Trevi Therapeutics (TRVI) stock is flying higher Wednesday following the release of positive trial data for its skin disease treatment! The post Trevi

By Benzinga
June 29, 2022

Why Trevi Therapeutics Shares Trading Higher Today?

Trevi Therapeutics Inc (NASDAQ: TRVI) has announced positive results from its Phase 2b/3 PRISM trial of Haduvio in treating prurigo nodularis, a ch

By Seeking Alpha
May 14, 2022

Trevi Therapeutics' (TRVI) CEO Jennifer Good on Q1 2022 Results - Earnings Call Transcript

Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Jennifer Good – President and

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.